Strategies to increase responsiveness to hepatitis B vaccination in adults with HIV-1
- PMID: 23174382
- PMCID: PMC4141523
- DOI: 10.1016/S1473-3099(12)70243-8
Strategies to increase responsiveness to hepatitis B vaccination in adults with HIV-1
Abstract
HIV and hepatitis B virus co-infection leads to substantially increased morbidity and mortality compared with either infection alone. Immunisation with hepatitis B virus vaccine is the most effective way to prevent the infection in people with HIV; however, these patients have decreased vaccine responses and a short duration of protection compared with immunocompetent individuals. Control of HIV replication with highly active antiretroviral therapy and increased CD4 cell counts are associated with improved immune responses to hepatitis B vaccination. New vaccination strategies, such as increased vaccine dose, use of the intradermal route, and addition of adjuvants, could improve response rates in adults with HIV.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Similar articles
-
HIV viraemia during hepatitis B vaccination shortens the duration of protective antibody levels.HIV Med. 2015 Mar;16(3):161-7. doi: 10.1111/hiv.12189. Epub 2015 Jan 14. HIV Med. 2015. PMID: 25586899
-
Hepatitis B vaccine: a seven-year study of adherence to the immunization guidelines and efficacy in HIV-1-positive adults.Int J Infect Dis. 2008 Nov;12(6):e77-83. doi: 10.1016/j.ijid.2008.05.1226. Epub 2008 Aug 23. Int J Infect Dis. 2008. PMID: 18723381
-
Vaccination against hepatitis B with 4-double doses increases response rates and antibodies titers in HIV-infected adults.Vaccine. 2012 Sep 7;30(41):5973-7. doi: 10.1016/j.vaccine.2012.07.028. Epub 2012 Jul 21. Vaccine. 2012. PMID: 22828589 Clinical Trial.
-
Hepatitis B Vaccination and Waning Hepatitis B Immunity in Persons Living with HIV.Curr HIV/AIDS Rep. 2019 Oct;16(5):395-403. doi: 10.1007/s11904-019-00461-6. Curr HIV/AIDS Rep. 2019. PMID: 31468298 Review.
-
Hepatitis B vaccine effectiveness in the face of global HBV genotype diversity.Expert Rev Vaccines. 2011 Dec;10(12):1709-15. doi: 10.1586/erv.11.151. Expert Rev Vaccines. 2011. PMID: 22085174 Review.
Cited by
-
Immune response to hepatitis B vaccine among children under 5 years in Africa: a meta-analysis.Trop Med Health. 2024 Apr 1;52(1):28. doi: 10.1186/s41182-024-00594-4. Trop Med Health. 2024. PMID: 38561838 Free PMC article. Review.
-
Seroprevalence of ANTI-SARS-CoV-2 antibodies in patients with inflammatory bowel disease.Sci Rep. 2023 Apr 29;13(1):7044. doi: 10.1038/s41598-023-33402-w. Sci Rep. 2023. PMID: 37120662 Free PMC article.
-
Achieving protection against HBV in HIV patients: Finding the best strategy.Hum Vaccin Immunother. 2016 Dec;12(12):3166-3167. doi: 10.1080/21645515.2016.1215394. Epub 2016 Aug 15. Hum Vaccin Immunother. 2016. PMID: 27668887 Free PMC article.
-
Emerging challenges in managing hepatitis B in HIV patients.Curr HIV/AIDS Rep. 2015 Sep;12(3):344-52. doi: 10.1007/s11904-015-0275-7. Curr HIV/AIDS Rep. 2015. PMID: 26156570 Review.
-
Vaccinations for the HIV-Infected Adult: A Review of the Current Recommendations, Part I.Infect Dis Ther. 2017 Sep;6(3):303-331. doi: 10.1007/s40121-017-0166-x. Epub 2017 Aug 4. Infect Dis Ther. 2017. PMID: 28779442 Free PMC article. Review.
References
-
- Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 2006;44(1 suppl):S6–9. - PubMed
-
- World Health Organization [accessed Aug 24, 2012];Global Health Observatory: HIV/AIDS. http://www.who.int/gho/hiv/en/
-
- Spradling PR, Richardson JT, Buchacz K, Moorman AC, Brooks JT. Prevalence of chronic hepatitis B virus infection among patients in the HIV Outpatient Study, 1996–2007. J Viral Hepat. 2010;17:879–86. - PubMed
-
- Kellerman SE, Hanson DL, McNaghten AD, Fleming PL. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. J Infect Dis. 2003;188:571–77. - PubMed
-
- Lewden C, Salmon D, Morlat P, et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol. 2005;34:121–30. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U01AI69418/AI/NIAID NIH HHS/United States
- U19 AI090023/AI/NIAID NIH HHS/United States
- KL2 TR000455/TR/NCATS NIH HHS/United States
- AI074492/AI/NIAID NIH HHS/United States
- U19 AI057266/AI/NIAID NIH HHS/United States
- U01 AI069418/AI/NIAID NIH HHS/United States
- TL1 RR025010/RR/NCRR NIH HHS/United States
- U19 AI090023-01/AI/NIAID NIH HHS/United States
- TL1 TR000456/TR/NCATS NIH HHS/United States
- UL1 TR000454/TR/NCATS NIH HHS/United States
- KL2RR02500/RR/NCRR NIH HHS/United States
- AI05726/AI/NIAID NIH HHS/United States
- UL1 RR025008/RR/NCRR NIH HHS/United States
- P30 AI050409/AI/NIAID NIH HHS/United States
- R38 AI140299/AI/NIAID NIH HHS/United States
- T32 AI074492/AI/NIAID NIH HHS/United States
- UL1RR025008/RR/NCRR NIH HHS/United States
- UM1 AI068614/AI/NIAID NIH HHS/United States
- KL2 RR025009/RR/NCRR NIH HHS/United States
- AI068614/AI/NIAID NIH HHS/United States
- AI50409-07/AI/NIAID NIH HHS/United States
- U01 AI068614/AI/NIAID NIH HHS/United States
- N01 A180005/PHS HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials